CD274 and cancer: In all studies, ICPIs, in particular anti-PD-1/PD-L1 antibodies were the most popular class selected as a combination agent, while others include chemotherapy, cancer vaccines, and other immunotherapies targeting CTLA-4, lymphocyte-activation gene 3, C-C motif chemokine receptor type 4 are also under investigation.